Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Ignacio Isola, MD, David Moreno, MD, Esther Moga, MD PhD, Mari-Pau Mena, PhD, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, MD PhD, M. Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Carlos Fernandez de Larrea, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-139737

Published: 2020

Journal Articles

Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma

Carlos Fernandez de Larrea, MD PhD, Mette Staehr, PhD, Andrea Lopez, Yunxin Chen, MBBS, Terence J Purdon, MS, Khong Y. Ng, PhD, Hans Wendel, MD, Renier J. Brentjens, MD PhD, Eric L Smith, MD PhD

Blood (2019) 134 (Supplement_1): 136.

https://doi.org/10.1182/blood-2019-126145

Published: 2019

Journal Articles

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Blood (2018) 132 (Supplement 1): 959.

https://doi.org/10.1182/blood-2018-99-119717

Published: 2018

Journal Articles

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Carlos Fernandez de Larrea, MD PhD, Ignacio Isola, MD, Esther Moga, Maria Teresa Cibeira, MD PhD, Ester Lozano, PhD, Juan I. Arostegui, Montserrat Elena, Natalia Tovar, MD PhD, Jordi Yague, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 4514.

https://doi.org/10.1182/blood-2018-99-117385

Published: 2018

Journal Articles

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

Luis Gerardo Rodríguez-Lobato, MD PhD, Carlos Fernández De Larrea, MD PhD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Joan Bladé, MD PhD, Laura Rosinol, MD PhD

Blood (2018) 132 (Supplement 1): 5573.

https://doi.org/10.1182/blood-2018-99-112089

Published: 2018

Journal Articles

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Blood (2018) 132 (Supplement 1): 589.

https://doi.org/10.1182/blood-2018-99-110471

Published: 2018

Journal Articles

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

Carlos Fernandez de Larrea, MD PhD, Tania Diaz, PhD, Alfons Navarro, PhD, Ester Lozano, PhD, Mari-Pau Mena, PhD, Ignacio Isola, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 3155.

https://doi.org/10.1182/blood-2018-99-112222

Published: 2018

Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Blood (2018) 132 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2018-99-117089

Published: 2018

Journal Articles

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Carlos Fernandez de Larrea, MD PhD, David Moreno, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Ignacio Isola, MD, Laura Magnano, MD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 1610.

https://doi.org/10.1182/blood-2018-99-115038

Published: 2018

Journal Articles

Bone Marrow Plasma Cell Infiltration in Light Chain Amyloidosis: Impact on Organ Involvement and Outcome

Carlos Fernandez de Larrea, MD PhD, Luis Gerardo Rodríguez-Lobato, MD, Natalia Tovar, MD PhD, Laura Magnano, MD, Ignacio Isola, MD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Mª Teresa Cibeira, MD PhD

Blood (2017) 130 (Supplement 1): 5365.

https://doi.org/10.1182/blood.V130.Suppl_1.5365.5365

Published: 2017

Journal Articles

Micrornas in Bone Marrow Mesenchymal Stromal Cells Are Differentially Expressed According to Response in Multiple Myeloma

Carlos Fernandez de Larrea, MD PhD, Tania Diaz, PhD, Alfons Navarro, PhD, Ester Lozano, PhD, Mari-Pau Mena, PhD, Ignacio Isola, MD, Mª Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2017) 130 (Supplement 1): 4362.

https://doi.org/10.1182/blood.V130.Suppl_1.4362.4362

Published: 2017

Journal Articles

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

Raquel Jiménez, MD, Laura Rosinol, MD PhD, Maria Teresa Cibeira, MD PhD, Carlos Fernández De Larrea, MD PhD, Esther Blade, Natalia Tovar, MD PhD, Joan Bladé, MD PhD

Blood (2017) 130 (Supplement 1): 3140.

https://doi.org/10.1182/blood.V130.Suppl_1.3140.3140

Published: 2017

Journal Articles

Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

Raquel Jiménez-Segura, PhD, Carlos Fernández De Larrea, MD PhD, Maite Cibeira, MD PhD, Natalia Tovar, Esther Bladé, Ignacio Isola, MD PhD, Joan Bladé, Laura Rosiñol

Blood (2016) 128 (22): 5709.

https://doi.org/10.1182/blood.V128.22.5709.5709

Published: 2016

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

Salvage Therapy for Multiple Myeloma with Lenalidomide-Based Regimens: Impact of Single Nucleotide Polymorphisms Related to miRNA Pathways

Carlos Fernández de Larrea, MD PhD, Tania Díaz, PhD, María Teresa Cibeira, MD PhD, Natalia Tovar, MD, Alfons Navarro, PhD, Laura Rosiñol, MD PhD, Raquel Jiménez, MD, Rut Tejero, PhD, Mariano Monzó, MD PhD, Joan Bladé, MD PhD

Blood (2014) 124 (21): 2045.

https://doi.org/10.1182/blood.V124.21.2045.2045

Published: 2014

Journal Articles

Smoldering Multiple Myeloma: Impact of the Evolving Pattern on Early Progression

Carlos Fernández de Larrea, MD PhD, Ignacio Isola, MD, María Teresa Cibeira, MD PhD, Laura Rosiñol, MD PhD, Xavier Calvo, MD, Natalia Tovar, MD, Montserrat Elena, MD, Laura Magnano, MD, Juan I. Aróstegui, MD PhD, María Rozman, MD PhD, Jordi Yagüe, MD PhD, Joan Bladé, MD PhD

Blood (2014) 124 (21): 3363.

https://doi.org/10.1182/blood.V124.21.3363.3363

Published: 2014

Journal Articles

Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution

Carlos Fernández de Larrea, MD, PhD, Laura Magnano, MD, Montserrat Elena, MD, María Teresa Cibeira, MD, PhD, Natalia Tovar, MD, Juan I. Aróstegui, MD, PhD, Fabiola Pedrosa, MS, Laura Rosiñol, MD, Xavier Filella, MD, PhD, Jordi Yagüe, MD, PhD, Joan Bladé, MD, PhD

Blood (2013) 122 (21): 3132.

https://doi.org/10.1182/blood.V122.21.3132.3132

Published: 2013

Journal Articles

Plasma Circulating Proteasomes As Biomarkers Along Natural History Of Asymptomatic Monoclonal Gammopathies

Carlos Fernández de Larrea, MD, PhD, Adriana Zingone, MD, PhD, Elisabet E. Manasanch, MD, Neha Korde, MD, Peter Wu, Rene Costello, MS, Diamond Zuchlinski, RN, Marcia Mulquin, RN, Debra Burton, Irina Maric, MD, Katherine R Calvo, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Mark Roschewski, MD, Ola Landgren, MD, PhD

Blood (2013) 122 (21): 3133.

https://doi.org/10.1182/blood.V122.21.3133.3133

Published: 2013

NARROW

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Bone Marrow Plasma Cell Infiltration in Light Chain Amyloidosis: Impact on Organ Involvement and Outcome

Micrornas in Bone Marrow Mesenchymal Stromal Cells Are Differentially Expressed According to Response in Multiple Myeloma

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

Efficacy of Novel Agents on Soft-Tissue Plasmacytomas in Patients with Relapsed Multiple Myeloma

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Salvage Therapy for Multiple Myeloma with Lenalidomide-Based Regimens: Impact of Single Nucleotide Polymorphisms Related to miRNA Pathways

Smoldering Multiple Myeloma: Impact of the Evolving Pattern on Early Progression

Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution

Plasma Circulating Proteasomes As Biomarkers Along Natural History Of Asymptomatic Monoclonal Gammopathies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only